# A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

> **NCT03559699** · PHASE3 · COMPLETED · sponsor: **Agios Pharmaceuticals, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Pyruvate Kinase Deficiency
- Anemia, Hemolytic

## Interventions

- **DRUG:** AG-348

## Key facts

- **NCT ID:** NCT03559699
- **Lead sponsor:** Agios Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-26
- **Primary completion:** 2020-11-12
- **Final completion:** 2020-11-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03559699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03559699, "A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03559699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*